康惠制药(603139) - 2025 Q2 - 季度业绩预告

Performance Forecast Overview The company anticipates a significant loss for the first half of 2025, with specific net profit figures provided for both attributable and non-recurring adjusted results Key Highlights Shaanxi Kanghui Pharmaceutical Co., Ltd. expects a loss for the first half of 2025, with net profit attributable to shareholders estimated at approximately -38 million RMB and net profit attributable to shareholders after deducting non-recurring gains and losses estimated at approximately -41 million RMB Estimated Financial Performance for H1 2025 | Indicator | Estimated Amount (Million RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -38 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | -41 | | Impact of Non-Recurring Gains/Losses | 2.6 | - The company anticipates a loss for the first half of 2025[3] Current Period Performance Forecast The company specified the performance forecast period for the first half of 2025 as January 1 to June 30, reiterated the projected loss figures, and emphasized that this forecast is a preliminary estimate unaudited by an accounting firm - The performance forecast period is January 1, 2025, to June 30, 2025[4] Key Estimated Financial Indicators for H1 2025 | Indicator | Estimated Amount (Million RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -38 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | -41 | - This performance forecast is a preliminary estimate based on the company's operating conditions and has not been audited by an accounting firm[6] H1 2024 Performance Review This section reviews the company's financial performance for the first half of 2024, highlighting the previously incurred losses as a comparative context H1 2024 Performance Details The company disclosed its financial data for the first half of 2024, indicating a prior loss state, which serves as a comparative baseline for the current period's projected loss, with net profit attributable to parent company shareholders at -8.7020 million RMB H1 2024 Financial Performance | Indicator | H1 2024 Amount (Million RMB) | | :--- | :--- | | Total Profit | -9.8818 | | Net Profit Attributable to Parent Company Shareholders | -8.7020 | | Net Profit After Deducting Non-Recurring Gains/Losses | -15.9866 | | Earnings Per Share (RMB) | -0.09 | Analysis of Main Reasons for Projected Loss This section analyzes the primary factors contributing to the projected loss, including increased parent company costs and significant losses from a controlled subsidiary Increase in Parent Company Costs and Expenses Influenced by pharmaceutical policies and industry conditions, the parent company actively adjusted its operating strategy, expanded sales channels (including secondary and tertiary terminals), and optimized product structure (increasing sales of agency products), leading to a significant increase in costs and expenses in H1 2025 compared to the previous year, thus impacting overall performance - Affected by pharmaceutical policies and industry environment, the company actively adjusted its operating strategy, maintaining a sales-centric approach[8] - The company continues to consolidate hospital sales and vigorously expand secondary and tertiary terminal sales such as community hospitals, clinics, and pharmacies[8] - The company adjusted its sales product structure, increasing sales of agency products, which led to a significant increase in costs and expenses in H1 2025 compared to the previous year[8] Impact of Losses from Controlled Subsidiary Controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. incurred significant fixed asset depreciation and financing loan interest expenses, coupled with unexpected product market supply-demand changes leading to lower-than-expected revenue, resulting in substantial losses in H1 2025 and a significant impact on the company's current period performance - Controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. incurred significant fixed asset depreciation and financing loan interest expenses[8] - Shaanxi Youbang's product market supply and demand relationship is highly volatile, leading to lower-than-expected product revenue[8] - Shaanxi Youbang continued to incur substantial losses in H1 2025, impacting the company's current period performance[8] Risk Warning and Disclosures This section provides crucial risk warnings and disclosures, emphasizing the preliminary nature of the financial forecast and advising investors to exercise caution Risk Warning The company reiterates that this performance forecast is a preliminary calculation based on the finance department's professional judgment and has not been audited by a certified public accountant, reminding investors to be aware of potential investment risks - This performance forecast is a preliminary calculation by the company's finance department based on its professional judgment and has not yet been audited by a certified public accountant[9] Other Disclosures The company reminds investors that the performance forecast data is only a preliminary calculation, and the final accurate financial data will be subject to the company's officially disclosed '2025 Semi-Annual Report,' reiterating investment risks - The performance forecast data above is only preliminary; the final accurate financial data will be based on the company's officially disclosed '2025 Semi-Annual Report'[10] - Investors are kindly reminded to pay attention to investment risks[10]